Phase 3
Completed N=53
Biological Markers of Response to Treatment in Major Depressive Disorder
Source: ClinicalTrials.gov NCT00361218 ↗Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcomePrimary: Serum Brain-derived Neurotrophic Factor (BDNF) Levels — 6077.270; 4393.24 pg/mL
Summary
The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or escitalopram).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum Brain-derived Neurotrophic Factor (BDNF) Levels |
6077.270; 4393.24 | — |
| PRIMARY Quantitative Electroencephalogram (QEEG) Parameters as Predictors of Response |
— | — |
Eligibility Criteria
Inclusion Criteria
- Ages 18-65
- Meet criteria for current Major Depressive Disorder
- Antidepressant medication-free for at least 2 weeks prior to the start of the study
Exclusion Criteria
- Pregnant or breastfeeding women
- Anyone who is suicidal
- Anyone with an unstable medical condition (cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological), substance abuse problem within the past 6 months, psychoses (past or current), hypothyroidism, or hypomania
- Anyone currently taking an SSRI
- Past intolerance to Lexapro or Celexa
Data sourced from ClinicalTrials.gov (NCT00361218). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.